Cited 2 times in
Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 조병철 | - |
dc.date.accessioned | 2024-02-15T06:59:55Z | - |
dc.date.available | 2024-02-15T06:59:55Z | - |
dc.date.issued | 2023-12 | - |
dc.identifier.issn | 1556-0864 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/198109 | - |
dc.description.abstract | Introduction: Lazertinib, a third-generation mutant-selective EGFR tyrosine kinase inhibitor, improved progression-free survival compared with gefitinib in the phase 3 LASER301 study (ClinicalTrials.gov Identifier: NCT04248829). Here, we report the efficacy of lazertinib and gefitinib in patients with baseline central nervous system (CNS) metastases. Methods: Treatment-naive patients with EGFR-mutated advanced NSCLC were randomized one-to-one to lazertinib (240 mg/d) or gefitinib (250 mg/d). Patients with asymptomatic or stable CNS metastases were included any planned radiation, surgery, or steroids were completed more than 2 weeks before randomization. For patients with CNS metastases confirmed at screening or subsequently suspected, CNS imaging was performed every 6 weeks for 18 months, then every 12 weeks. End points assessed by blinded independent central review and Response Evaluation Criteria in Solid Tumors version 1.1 included intracranial progression-free survival, intracranial objective response rate, and intracranial duration of response.Results: Of the 393 patients enrolled in LASER301, 86 (lazertinib, n = 45; gefitinib, n = 41) had measurable and or non measurable baseline CNS metastases. The median intracranial progression-free survival in the lazertinib group was 28.2 months (95% confidence interval [CI]: 14.8-28.2) versus 8.4 months (95% CI: 6.7-not reached [NR]) in the gefitinib group (hazard ratio = 0.42, 95% CI: 0.20-0.89, p = 0.02). Among patients with measurable CNS lesions, the intracranial objec- tive response rate was numerically higher with lazertinib (94%; n = 17) versus gefitinib (73%; n = 11, p = 0.124). The median intracranial duration of response with lazertinib was NR (8.3-NR) versus 6.3 months (2.8-NR) with gefitinib. Tolerability was similar to the overall LASER301 population. Conclusions: In patients with CNS metastases, lazertinib significantly improved intracranial progression-free sur- vival compared with gefitinib, with more durable responses. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | English | - |
dc.publisher | Elsevier | - |
dc.relation.isPartOf | JOURNAL OF THORACIC ONCOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung* / drug therapy | - |
dc.subject.MESH | Carcinoma, Non-Small-Cell Lung* / genetics | - |
dc.subject.MESH | Central Nervous System | - |
dc.subject.MESH | ErbB Receptors / genetics | - |
dc.subject.MESH | Gefitinib / pharmacology | - |
dc.subject.MESH | Gefitinib / therapeutic use | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lung Neoplasms* / drug therapy | - |
dc.subject.MESH | Lung Neoplasms* / genetics | - |
dc.subject.MESH | Mutation | - |
dc.subject.MESH | Protein Kinase Inhibitors / pharmacology | - |
dc.subject.MESH | Protein Kinase Inhibitors / therapeutic use | - |
dc.subject.MESH | Quinazolines / pharmacology | - |
dc.title | Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Ross A Soo | - |
dc.contributor.googleauthor | Byoung Chul Cho | - |
dc.contributor.googleauthor | Joo-Hang Kim | - |
dc.contributor.googleauthor | Myung-Ju Ahn | - |
dc.contributor.googleauthor | Ki Hyeong Lee | - |
dc.contributor.googleauthor | Anastasia Zimina | - |
dc.contributor.googleauthor | Sergey Orlov | - |
dc.contributor.googleauthor | Igor Bondarenko | - |
dc.contributor.googleauthor | Yun-Gyoo Lee | - |
dc.contributor.googleauthor | Yueh Ni Lim | - |
dc.contributor.googleauthor | Sung Sook Lee | - |
dc.contributor.googleauthor | Kyung-Hee Lee | - |
dc.contributor.googleauthor | Yong Kek Pang | - |
dc.contributor.googleauthor | Chin Heng Fong | - |
dc.contributor.googleauthor | Jin Hyoung Kang | - |
dc.contributor.googleauthor | Chun Sen Lim | - |
dc.contributor.googleauthor | Pongwut Danchaivijitr | - |
dc.contributor.googleauthor | Saadettin Kilickap | - |
dc.contributor.googleauthor | James Chih-Hsin Yang | - |
dc.contributor.googleauthor | Cagatay Arslan | - |
dc.contributor.googleauthor | Hana Lee | - |
dc.contributor.googleauthor | Seong Nam Park | - |
dc.contributor.googleauthor | Irfan Cicin | - |
dc.identifier.doi | 10.1016/j.jtho.2023.08.017 | - |
dc.contributor.localId | A03822 | - |
dc.relation.journalcode | J01909 | - |
dc.identifier.eissn | 1556-1380 | - |
dc.identifier.pmid | 37865896 | - |
dc.subject.keyword | CNS | - |
dc.subject.keyword | Lazertinib | - |
dc.subject.keyword | NSCLC | - |
dc.subject.keyword | TKI | - |
dc.contributor.alternativeName | Cho, Byoung Chul | - |
dc.contributor.affiliatedAuthor | 조병철 | - |
dc.citation.volume | 18 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 1756 | - |
dc.citation.endPage | 1766 | - |
dc.identifier.bibliographicCitation | JOURNAL OF THORACIC ONCOLOGY, Vol.18(12) : 1756-1766, 2023-12 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.